

Jiri Neuzil obtained his PhD from Institute of Microbiology of the Czech Academy of Sciences in Prague. After short and long-term research projects in the Institute of Enzymology, Hungarian Academy of Sciences (Budapest, Hungary), Institute of Biochemistry and Molecular Biology, Technical University (West Berlin, Germany), and Department of Biochemistry, University of Cambridge (UK), he was a post-doctoral Fellow in the Heart Research Institute (Sydney, NSW, Australia). In 1998-2001, he was a Group Leader in the Institute of Circulatory Diseases (Ludwig Maximilian University, Munich, Germany), after which he spent one year as a Visiting Research Fellow in Department of Experimental Pathology, University of Linköping (Sweden). From 2002, he has been staff of Griffith University (Southport, Qld, Australia), and from 2007, he has a conjoint position in the Institute of Biotechnology, Czech Academy of Sciences (Prague-West), where he is the Head of the Molecular Therapy Group. His focus is on mitochondria and their role in cancer initiation and progression and as a target for cancer therapy, with one mitochondrial agent being clinically tested. His other research interests involve horizontal transfer of mitochondria in cancer and other pathologies, the role of *de novo* pyrimidine synthesis in malignant conversion and organ regeneration, and the biology of mitochondrial complex II.

